2022
DOI: 10.1016/j.phoj.2022.10.152
|View full text |Cite
|
Sign up to set email alerts
|

Allopurinol adjuvant in acute lymphoblastic leukaemia maintenance treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(5 citation statements)
references
References 0 publications
0
5
0
Order By: Relevance
“…In the future, additional information can be included to assist in treating inherent drug-sensitive patients with protocol modulation 3 or adjuvant therapy. 24 The system developed to support the e-clinic can be adapted to clinical decision-making software. [25][26][27] This will facilitate the standardization of MT therapy across centers in countries the size of India.…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…In the future, additional information can be included to assist in treating inherent drug-sensitive patients with protocol modulation 3 or adjuvant therapy. 24 The system developed to support the e-clinic can be adapted to clinical decision-making software. [25][26][27] This will facilitate the standardization of MT therapy across centers in countries the size of India.…”
Section: Discussionmentioning
confidence: 99%
“…The digitized longitudinal data eases optimal dose titration practice. In the future, additional information can be included to assist in treating inherent drug-sensitive patients with protocol modulation 3 or adjuvant therapy 24 . The system developed to support the e-clinic can be adapted to clinical decision-making software 25–27 .…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations